AUS
NZ
UK
CA
USA
IND
Healthcare
Actinogen’s ASX Move Signals a Fresh Chapter in Australian Biotech
December 23, 2025 04:48 PM AEDT| By SamActinogen Medical advances capital transparency through a new ASX quotation, reinforcing disciplined governance and supporting long-term innovation within Australia’s listed biotechnology sector.
Actinogen Medical Advances Market Access With New ASX Share Quotation
December 23, 2025 04:24 PM AEDT| By SamActinogen Medical’s ASX share quotation highlights how Australian listed companies manage capital structure updates within a transparent and regulated market environment.
Neurizon Therapeutics Advances ALS Research With New Capital
December 23, 2025 12:46 PM AEDT| By SamNeurizon Therapeutics advances its ALS clinical journey with new funding support, strengthening trial readiness and research momentum while remaining active within the ASX stock market ecosystem.
Dimerix Licensing Stability Signals Confidence After US Pharma Deal
December 22, 2025 12:55 PM AEDT| By SamThis article explores how Dimerix’s US licensing arrangement stays intact after a major pharmaceutical acquisition, outlining implications for drug development, global partnerships, and the broader ASX stock market landscape.
Illuccix Progress in China Strengthens Telix’s Global Pathway
December 22, 2025 12:35 PM AEDT| By SamTelix Pharmaceuticals advances its global imaging strategy as China study outcomes strengthen regulatory confidence and support broader adoption of precision diagnostics across key oncology markets.
Healthcare Equipment Focus as ResMed Appears in ASX 100 Landscape
December 19, 2025 06:14 PM AEDT| By SamResMed operates within the healthcare equipment sector, combining medical devices and digital platforms while maintaining visibility across major Australian indices.
Memphasys and the ASX 300 Setting in the Local Healthcare Space
December 19, 2025 06:09 PM AEDT| By SamMemphasys released a corporate update on additional share quotation, reflecting standard disclosure practices within the Australian healthcare sector and the ASX framework.
Prescient Therapeutics Advances Europe Trial Path for PTX
December 19, 2025 05:15 PM AEDT| By SamThis article explores how Prescient Therapeutics is expanding its European clinical program, strengthening global research efforts, and advancing PTX development through regulated trial pathways.
Ansell Limited’s Measured Approach to Debt and Stability
December 19, 2025 05:10 PM AEDT| By SamThis article explores how Ansell Limited manages debt responsibly, supported by cash flow discipline, balance sheet strength, and long-term business fundamentals within the Australian equity landscape.
Are SHL Shares at a Turning Point for Long-Term Watchers?
December 19, 2025 05:04 PM AEDT| By SamAn in-depth look at Sonic Healthcare and Xero, exploring business models, market positioning, and valuation perspectives shaping discussion across the Australian share market.
Fresh Capital Update Signals Strategic Momentum at 4DMedical
December 19, 2025 04:06 PM AEDT| By SamAn in-depth look at 4DMedical’s latest ASX share quotation move, exploring capital structure dynamics, sector context, and broader market relevance in a clear, investor-friendly format.
Amplia Expands Cancer Research With New Global Collaboration
December 19, 2025 12:27 PM AEDT| By SamAn in-depth look at Amplia Therapeutics’ expanded research collaboration, its cancer pipeline direction, and how advanced preclinical models are shaping future oncology studies.
Radiopharm Theranostics Responds to ASX Rule Compliance Review
December 18, 2025 03:05 PM AEDT| By SamRadiopharm Theranostics has addressed a listing rule oversight, outlining governance enhancements and external advisory support to strengthen compliance and align future capital activities with ASX requirements.
Orthocell Reaches Key US Commercial Milestone With Remplir Uptake
December 18, 2025 12:35 PM AEDT| By SamOrthocell has reached an early US commercial milestone for Remplir, signalling growing adoption momentum supported by surgeon engagement, hospital access progress, and a disciplined international expansion strategy.
Regulatory Crossroads Put Telix Under the Biotech Spotlight
December 17, 2025 08:15 PM AEDT| By SamThis article explores how regulatory feedback and legal scrutiny reshaped sentiment around Telix, while ongoing clinical and operational progress kept long-term focus alive.
Understanding Cochlear’s Market Strength and Financial Signals
December 17, 2025 07:37 PM AEDT| By Team Kalkine MediaThis article explores how Cochlear’s business model, financial discipline, and global footprint shape market confidence, while explaining key valuation signals in a clear and accessible way.
CSL Limited Navigates Shifting Market Expectations
December 17, 2025 06:24 PM AEDT| By SamThis article explores CSL Limited’s evolving business narrative, capital actions, and sector positioning as market focus shifts toward execution, stability, and long-term healthcare demand across the ASX stock market.
CSL Ltd Overview within the ASX Healthcare Segment and ASX 100
December 17, 2025 04:32 PM AEDT| By SamCSL Ltd functions within the healthcare sector, maintains global operations, and holds inclusion in key Australian equity indices supporting market diversity.
Cancer Drug Progress Reshapes Percheron’s Clinical Journey
December 17, 2025 04:20 PM AEDT| By SamThis article explores how Percheron Therapeutics is reshaping its clinical strategy through oncology research progress, pipeline focus, and broader market relevance within the ASX stock market ecosystem.
Inside Biotech: Telix and the Weight of Regulatory Uncertainty
December 17, 2025 04:05 PM AEDT| By SamThis article explores how regulatory reviews and legal scrutiny are shaping sentiment around Telix Pharmaceuticals, while pipeline advancement and operational progress continue within the evolving ASX stock market landscape.
Advertise your brand on Kalkine Media